A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Nirogacestat (Primary)
- Indications Fibroma
- Focus Registrational; Therapeutic Use
- Acronyms DeFi
- Sponsors SpringWorks Therapeutics
- 05 Dec 2019 Planned number of patients changed from 118 to 135.
- 15 Nov 2019 Planned number of patients changed from 105 to 118.
- 12 Apr 2019 Planned initiation date changed from 31 Mar 2019 to 30 Apr 2019.